Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 11 Results

Title
Intervention Indication Therapeutic Area Year Actions
Adstiladrin for high-grade, BCG unresponsive non-muscle-invasive bladder cancer Adstiladrin (Nadofaragene firadenovec; rAd-IFN/Syn3; Instiladrin) Bladder cancer Urological Cancer 2019 View  |  Download
Atezolizumab for muscle-invasive urothelial carcinoma –adjuvant Atezolizumab (Tecentriq; MPDL3280A) Bladder cancer Urological Cancer 2019 View  |  Download
Avelumab in addition to best supportive care for locally advanced or metastatic urothelial cancer Avelumab (Bavencio; MSB-0010718C) Bladder cancer Urological Cancer 2019 View  |  Download
Durvalumab (Imfinzi) for locally advanced or metastatic urothelial bladder cancer – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Bladder cancer Urological Cancer 2017 View  |  Download
Durvalumab in combination with tremelimumab and chemotherapy for unresectable, locally advanced or metastatic urothelial cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Bladder cancer Urological Cancer 2020 View  |  Download
Durvalumab in combination with Tremelimumab for locally advanced or metastatic urothelial bladder cancer – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Bladder cancer Urological Cancer 2017 View  |  Download
Durvalumab with Bacillus Calmette-Guerin for treating non-muscle invasive bladder cancer Bacillus Calmette-Guerin (BCG; BCG Tokyo-172; OncoTICE) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Bladder cancer Urological Cancer 2022 View  |  Download
Durvalumab with gemcitabine-cisplatin neoadjuvant treatment and durvalumab adjuvant treatment for muscle-invasive bladder cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Bladder cancer Urological Cancer 2022 View  |  Download
Nivolumab in combination with ipilimumab for cisplatin-ineligible patients with untreated, unresectable or metastatic urothelial cancer– first line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Bladder cancer Oncology , Urological Cancer 2021 View  |  Download
Oportuzumab monatox for non-muscle invasive bladder cancer - second line Oportuzumab monatox (Vicinium; VB4-845; Proxinium) Bladder cancer Urological Cancer 2020 View  |  Download
1 2
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications